Nelson Advisors in 2026: the boutique bank that became European HealthTech's house commentator
Nelson Advisors has spent 2026 doing two things at once: closing lower-mid-market healthtech deals and telling the rest of the market what it sees. The London-based firm, co-founded by partners Lloyd Price and Paul Hemings, specialises in mergers, acquisitions, partnerships and investments for HealthTech, MedTech, Digital Health, Health IT and Health AI companies with enterprise values between roughly $25 million and $250 million.
What sets the firm apart is the volume and specificity of its public analysis. Through its Google News-approved platform healthcare.digital, a weekly newsletter with more than 5,000 subscribers, a UK HealthTech Pulse series and a growing library of deep-dive reports, Nelson Advisors publishes forecasts with numbers attached and revisits them in public. In 2026 that output has included half-year prediction updates, a 20-country "future leaders" series, strategic growth frameworks for 2027 and, due on 10th December 2026, a full European HealthTech Annual Report.
That combination of deal-side vantage point and willingness to be quoted has made the firm a regular source for trade and financial press, including Mergermarket, Healthcare Business International and Digital Health.
This article pulls together what Nelson Advisors has said about 2026, which predictions it has made for 2027, and where its views have surfaced in the press. Figures below are the firm's own or the data providers it cites, as of early November 2026.
The macro picture: record capital, narrower market
Nelson Advisors' central reading of 2026 is a paradox: more money than ever is flowing into European healthtech, yet the market is harder and more selective than at any point since 2019. In its Annual Report preview (19 October 2026) the firm calls this "concentration" and builds the whole report around explaining it.
The numbers it cites, drawn from Galen Growth, make the case. European digital health venture funding reached $6.2 billion in 2025, up 15 per cent and the fastest-growing region globally. The first half of 2026 added $5.9 billion, a 60 per cent rise on H1 2025. But that total came from only 190 deals, down from 283 a year earlier, and more than a third of it was one round: Isomorphic Labs' $2.1 billion Series B in May. Strip that out and the half was flat. Seed and angel activity has contracted sharply, deal counts are at their lowest since 2020, and the median time from first funding to exit has stretched from about eight years to nearly eleven.
The firm frames this as the end of the venture "funding escalator". Its October 2026 paper on founder bankers and the liquidity imperative traces the problem to 2020–21, when zero-rate money inflated entry valuations and subsidised unsustainable burn. By late 2024, invested capital in European Series B healthcare rounds had fallen roughly 84 per cent from the 2021 peak, and the gap between rounds had widened beyond 774 days towards 1,000.
The consequence, in Nelson Advisors' telling, is that M&A has become the default liquidity route. Its 2027 M&A hotspots piece notes global healthtech M&A logged 149 deals in Q1 2026 alone, on pace to beat 2025's 555, with private equity accounting for about a third and disclosed value of $22.7 billion already close to 2025's full-year total. The firm also flags a change in who is buying: Hims & Hers, RadNet, Sword Health, Radiology Partners, Universal Health Services and Oura all acquired European or Europe-exposed assets in the first eight months of the year.
Two more structural shifts round out the picture. First, the investor base has moved: US investors took part in 62 per cent of European late-stage digital health deals in 2025, triple the 2023 share, and every 2026 mega-round was led or co-led by a US or sovereign investor. Second, public capital has become the anchor of the European fund ecosystem, with the British Business Bank, Bpifrance, the European Investment Fund and the European Innovation Council now corner stoning most new health funds.
Six trends Nelson Advisors has tracked through 2026
1. Health AI is the operating assumption, not a category. The firm's most repeated line of the year is that AI stopped being a sub-sector. Every top-ten European healthtech round of 2026 was AI-framed, from Isomorphic's drug design to Neko Health's preventive scanning, Oviva's chronic care and Alan's insurance platform. UK health AI alone attracted $2.6 billion in H1, the second-largest AI vertical after enterprise software. The caveat, from its founders' guide, is that AI as the only differentiator is rarely a moat; a thin wrapper on cheap general-purpose models is the most exposed position in the market.
2. Ambient clinical documentation moved from pilot to procurement. NHS England set an April 2026 adoption expectation and published national guidance; Germany and France are about a year behind. The UK HealthTech Pulseseries through August tracked ambient voice scaling while drawing safety scrutiny, with the firm expecting safety findings to become a differentiator that rewards vendors with strong evidence and governance and pushes the long tail into consolidation.
3. From digital front doors to completed pathways. The 18–24 August Pulse argued the NHS focus has shifted from booking portals and chatbots to fixing drop-offs between referral, consultation and treatment. Tools that leave patients in administrative limbo face clinician pushback; startups with bi-directional integration and automated follow-up are winning pilots over point solutions.
4. Capital is barbelling. The firm describes a funding market split between small grants and procurement tickets at one end and billion-dollar consolidation plays at the other. Its August Pulse logged a £400k digital MSK procurement, a primary care accelerator and a £5 million NHS cancer innovation programme in a single week, alongside global digital health VC of $7.4 billion in H1 2026 where AI agents, chronic care and workforce tools took the mega-deals.
5. Regulation is being rebuilt in real time. The Commission's December 2025 MDR/IVDR simplification is working through Council and Parliament with adoption targeted for Q2 2027. The AI Act's Digital Omnibus, in force since July 2026, pushed high-risk obligations for AI medical devices to August 2028. The European Health Data Space applies from March 2027. In the UK, NHS England is being abolished, the Health Bill establishes a Single Patient Record, and the MHRA has published draft device rules with an international reliance route. Nelson Advisors calls this transition the single largest source of both risk and opportunity for anyone selling into European health systems.
6. Exits have bifurcated. No European digital health or health AI company has listed on any exchange in 2025 or 2026 to date. Ottobock's €808 million Frankfurt IPO in October 2025 was the only meaningful European medtech listing and trades about 15 per cent below issue. The US window, by contrast, reopened decisively: Hinge Health and Heartflow have more than doubled since listing, and Finnish-founded, US-domiciled Oura filed publicly in September 2026 for a Nasdaq IPO that could value it above $16 billion. Meanwhile, Sword Health's $285 million purchase of Kaia Health, RadNet's $269 million acquisition of Gleamer and Doctolib's purchase of Medicus Health illustrate what the firm calls sensible mid-sized outcomes rather than venture-scale home runs.
Predictions and forecasts: what the firm has put on the record
Nelson Advisors makes forecasts with dates and ranges, and it has updated them in public three times this year: a December 2025 outlook, a half-year revision at the end of June, and the October Annual Report preview. The table collects the calls that are still live.
Forecast | Nelson Advisors' call | Made |
European healthtech funding, full-year 2026 | $9 billion to $10.5 billion on Galen Growth's definition, a record | Oct 2026 |
Funding in 2027 | Similar range, with fewer and larger rounds | Oct 2026 |
H2 2026 M&A activity | Materially higher than H1; "bigger cheques, fewer bets" accelerates | Jun 2026 |
Venture deal count in H2 2026 | No broad-based recovery | Jun 2026 |
Sector re-rating in H2 2026 | None expected | Jun 2026 |
European-origin healthtech IPOs, 12 months to Sep 2027 | One to three; Oura near-certain, Doctolib the most plausible European-exchange candidate for late 2027 | Oct 2026 |
MDR/IVDR revision | Passes, with adoption targeted for Q2 2027 | Oct 2026 |
NHS ambient scribing framework | First awards made within the next 12 months | Oct 2026 |
Ambient AI vendors | First meaningful consolidation as the category commoditises | Oct 2026 |
Valuation gap | AI-validated, proof-rich companies at 6–8x revenue versus 3–5x for everyone else; gap widens before it narrows | Oct 2026 |
Pharma and healthtech | Deeper partnerships and acquisitions around companion digital tools, real-world-evidence platforms and adherence infrastructure, especially in metabolic, oncology and cardiovascular care | Jun 2026 |
The June update is worth reading as a scorecard in its own right. It opened by saying H1 2026 had confirmed the thesis set out the previous December: European HealthTech and MedTech were transitioning from a volume-driven to a value-driven market. The firm's headline call for the second half was that the concentration of capital into fewer, larger transactions would accelerate rather than reverse.
The longer-range view has already moved on to 2027. In its Strategic Growth Frameworks 2027 paper (22 October 2026) the firm describes the sector as having left speculative expansion for capital discipline and operational accountability. It cites health system EBITDA falling from 11.2 per cent of national health expenditure in 2019 to 8.9 per cent in 2024, with a projected 8.7 per cent by 2027, and notes that 71 per cent of health systems now enforce an "Epic-first" or equivalent stack rationalisation policy. The implication for vendors is that point solutions without a platform home face a shrinking buyer base.
A companion piece, European HealthTech M&A Hotspots for 2027, argues the character of the buyer has changed as much as the volume: US strategics and listed digital health platforms are now active acquirers of European assets, and private equity is a steady third of deal flow. A further article on lower-mid-market predictions for 2027 was published in late October and feeds into Section 15 of the December report.
There is a consistent house view beneath all of this. Nelson Advisors expects winners to be defined by verifiable clinical utility, regulatory defensibility, capital efficiency & platform integration, and it expects the market to keep paying a visible premium for those traits while the rest consolidates or exits at modest multiples.
Nelson Advisors in the press: interviews and quotes
The firm's partners are quoted most often when a deal, a policy or a listing needs a market read. Five examples from the past eighteen months show the range.
Mergermarket, August 2026: EPR owners weigh exits. Both partners were interviewed for a story on electronic patient record asset owners considering sales. Lloyd Price linked the timing to the SaaS valuation downturn driven by AI competition, which he described using the market shorthand "SaaSpocalypse". He argued that EPR providers should in the long run benefit from AI interest because they hold patient data competitors cannot access, which made the readiness to sell now somewhat surprising. Likely buyers, he said, were European sponsors and North American strategics, the latter either to tap the target's data or to block a rival from it.
Healthcare Business International, June 2026: the £900M NHS AI framework. Price told HBI that the framework centralises procurement and raises the bar on regulatory approval and data requirements, which for investors creates clearer visibility on winners: companies that secure framework access and win early bids are likely to compound advantage quickly. He expected immediate demand to concentrate in imaging, diagnostics, administrative automation and workforce optimisation. Source.
Healthcare Business International, June 2026: Boots after Sigma walks away. When Sigma Healthcare dropped out of talks to buy Boots, HBI asked Price about the options open to owner Sycamore Partners. He noted rival bidders had been put off by regulatory, financial and legal complexity when Sycamore bought the chain from Walgreens, and argued Boots' premium case rests on its combination of a dominant high-street footprint with a large online channel, plus its repositioning as a wellness platform across women's health, menopause, femtech, gut health and GLP-1 weight loss. If a trade sale failed, he said a London IPO was credible. Source.
Healthcare Business International, April 2026: Healthbridge buys AI scribe Nora. On a South African deal, Price told HBI the acquisition reflected a wider shift toward buying rather than building in-house. He added that AI-native startups were commanding revenue multiples of roughly 9x to 14x on the strength of proprietary data and automation potential, and that exit timelines were shortening, with many incubation-to-exit deals closing in under three years. Source.
Digital Health, 2025: the NHS App's missing killer feature. In an earlier piece on the NHS App, Price argued its core functions of booking GP appointments and ordering repeat prescriptions were already available in Patient Access, MyGP and AirMid, and that it needed a unique, proprietary function such as waiting-list validation for outpatients or live A&E waiting times to drive organic growth. Source.
The firm also takes the stage. Price joined the HealthTech predictions for 2026 panel at HealthTechX on 5 November 2025 alongside HeliosX, NICE and NEOM, debating whether investors would keep prioritising profitability over growth, whether 2026 would bring consolidation of point solutions, and how the EU AI Act's high-risk classification would slow medical AI deployment.
He spoke on the Prevention Not Cure founders panel at the HealthInvestor Healthcare Summit in London on 22 September 2026, and the firm's published 2026 events calendar runs from Digital Health Rewired and NHS ConfedExpo through HLTH Europe, HLTH USA, World Health Summit, Web Summit and MEDICA.
Referenced and sourced: how the firm's analysis travels
Beyond direct interviews, Nelson Advisors' research is syndicated and cited by third parties, and the firm in turn reads and annotates the big consultancies' reports for its audience.
Syndication. Industry aggregator Rama on Healthcare republishes the firm's weekly This Week in European HealthTech, MedTech and Health AI briefings and longer papers, which is how its views on clinical workflow automation, platform consolidation and EU regulatory alignment reach a US readership. The 25 September 2026 edition, for example, argued that European capital is bypassing consumer wellness in favour of "clinical plumbing", computational biology and specialised diagnostics, and that health systems are choosing calibrated domain-specific AI over general-purpose models.
Reading the majors. The firm regularly distils consultancy and industry reports into point-form summaries. Its 20 key points from the KPMG Global Tech Report 2026 Healthcare (published this week) pulls out findings such as early AI gains concentrating in HR, finance and procurement, 41 per cent of healthcare executives planning to lift cybersecurity spend by more than 10 per cent, and KPMG's conclusion that operating models rather than algorithms are now the binding constraint. Similar treatments cover HLTH Europe, where the firm published 10 reflections on the June 2026 Amsterdam event and its "Step Outside" theme.
Primary-source analysis. A distinctive strand of 2026 output is close reading of regulatory and capital-markets filings. The firm's analysis of Anthropic's Form S-1 (28 October 2026) argues the company's healthcare and life sciences push is a defence against commoditised model inference. Other pieces this autumn assess Gemini 4 Argon's clinical potential, Epic's agentic "Connectors", Zoom Clinical Notes, M42's Ossi platform, Microsoft's medical superintelligence work and the future of the NHS Federated Data Platform beyond Palantir.
Country and ecosystem research. The 20 Future European HealthTech and MedTech Leaders series profiles twenty founders, scientists and technologists in each of twenty European countries, and names Ghent, Porto and Wroclaw as hubs with the potential to become centres of excellence. Autumn pieces extended the lens to Switzerland's MedTech paradox, Australia's healthtech renaissance and celebrity investment in digital health.
Deal and sector commentary. Case-driven notes on Stryker's investment in CMR Surgical, Oura's patent litigation against Ultrahuman, Hinge Health's share price and the prospects for further digital MSK IPOs, and Sava Technologies' Series B give readers a transaction-level view that complements the macro forecasts. The lower-to-mid-market landscapepaper (29 August 2026) sets out the valuation logic the firm applies in that $25–250 million band: capital efficiency, demonstrated unit economics, verifiable clinical utility and regulatory defensibility rather than top-line growth.
A note on sourcing. The firm is explicit that it relies on third-party data, chiefly Galen Growth for venture funding, with Dealroom and CB Insights as broader and narrower comparators, and it labels advisers' and data providers' estimates as theirs rather than its own. That transparency is part of why its figures get picked up.
Conclusion: a forecaster that keeps score
The through-line in Nelson Advisors' 2026 output is consistency. The December 2025 thesis of a shift from volume to value was reaffirmed in June, and the October preview sharpened it into a single word, concentration, backed by funding data, deal counts and exit timelines. The firm's forecasts are specific enough to be wrong: a $9–10.5 billion funding range, one to three European-origin IPOs by September 2027, a 6–8x versus 3–5x valuation split. That is rarer than it should be among advisory firms, and it is why journalists keep calling.
For founders, the practical message is blunt. Cheap intelligence is not a moat; proof, integration and regulatory readiness are. For investors, the firm's view is that the lower-mid market between $25 million and $250 million is where European healthtech value actually gets realised, and that the buyer universe has widened to include US strategics and listed digital health platforms. For anyone selling into the NHS or EU health systems, the regulatory transition of 2026–28 is the risk and the opportunity in one.
The next checkpoint is 10 December 2026, when the European HealthTech 2026 Annual Report publishes with sixteen sections including 2027 predictions and twelve-month IPO calls. If the firm's record this year is any guide, it will be worth reading against what it said in June.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments